Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
Type:
Application
Filed:
September 14, 2012
Publication date:
April 11, 2013
Applicant:
AGENSYS, INC.
Inventors:
Arthur B. Raitano, Karen Jane Meyrick Morrison, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
Abstract: The invention described herein relates to novel nucleic acid sequences and their encoded proteins, referred to as 158P1D7 and variants thereof, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express 158P1D7 and variants thereof.
Abstract: A novel prostate tumor associated gene (designated 24P4C12) and its encoded protein is described. 24P4C12 is highly expressed in prostate tissue xenografts, providing evidence that it is turned on in at least some prostate cancers. 24P4C12 provides a diagnostic and/or therapeutic target for prostate and other cancers.
Type:
Grant
Filed:
August 20, 2007
Date of Patent:
February 26, 2013
Assignee:
Agensys, Inc.
Inventors:
Daniel E. Afar, Rene S. Hubert, Kahan Leong, Arthur B. Raitano, Douglas C. Saffran
Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
Type:
Grant
Filed:
April 9, 2010
Date of Patent:
January 8, 2013
Assignee:
Agensys, Inc.
Inventors:
Aya Jakobovits, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-chi Jia, Jean Gudas
Abstract: A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.
Type:
Application
Filed:
May 25, 2012
Publication date:
January 3, 2013
Applicant:
AGENSYS, INC.
Inventors:
Arthur B. Raitano, Aya Jakobovits, Pia M. Challita-Eid, Steven B. Kanner, Wangmao Ge, Juan J. Perez-Villar, Robert Kendall Morrison
Abstract: Antibody drug conjugates (ADC's) that bind to 24P4C12 protein and variants thereof are described herein. 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Type:
Grant
Filed:
March 5, 2010
Date of Patent:
November 13, 2012
Assignee:
Agensys, Inc.
Inventors:
Jean Gudas, Aya Jakobovits, Zili An, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-chi Jia, Dennis Benjamin, Ruth Moser, Peter Senter
Abstract: A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization.
Type:
Grant
Filed:
July 1, 2010
Date of Patent:
October 30, 2012
Assignee:
Agensys, Inc.
Inventors:
Arthur B. Raitano, Karen Jane Meyrick Morrison, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
October 2, 2012
Assignee:
Agensys, Inc.
Inventors:
Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
Type:
Grant
Filed:
October 3, 2006
Date of Patent:
August 14, 2012
Assignee:
Agensys, Inc.
Inventors:
Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Daniel E. H. Afar, Steven Chappell Mitchell, Mary Faris, Aya Jakobovits
Abstract: A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization.
Type:
Application
Filed:
April 18, 2012
Publication date:
August 9, 2012
Applicant:
AGENSYS, INC.
Inventors:
Arthur B. RAITANO, Pia M. Challita-Eid, Mary Faris, Rene S. Hubert, Wangmao Ge, Aya Jakobovits
Abstract: Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.
Type:
Grant
Filed:
September 14, 2010
Date of Patent:
August 7, 2012
Assignee:
Agensys, Inc.
Inventors:
Aya Jakobovits, Steven B. Kanner, Pia M. Challita-Eid, Juan J. Perez-Villar, Daulet Satpaev, Arthur B. Raitano, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Xiao-chi Jia, Jean Gudas
Abstract: A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.
Type:
Grant
Filed:
July 23, 2010
Date of Patent:
August 7, 2012
Assignee:
Agensys, Inc.
Inventors:
Aya Jakobovits, Mary Faris, Arthur B. Raitano, Robert Kendall Morrison, Douglas Saffran, Wangmao Ge, Pia M. Challita-Eid
Abstract: A novel gene 158P3D2 and its encoded protein, and variants thereof, are described wherein 158P3D2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 158P3D2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 158P3D2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 158P3D2 can be used in active or passive immunization.
Type:
Grant
Filed:
October 6, 2010
Date of Patent:
July 3, 2012
Assignee:
Agensys, Inc.
Inventors:
Arthur B. Raitano, Aya Jakobovits, Pia M. Challita-Eid, Steven B. Kanner, Wangmao Ge, Juan J. Perez-Villar, Robert Kendall Morrison
Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.
Type:
Grant
Filed:
March 27, 2009
Date of Patent:
June 26, 2012
Assignee:
Agensys, Inc.
Inventors:
Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Pia M. Challita-Eid, Arthur B. Raitano
Abstract: A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization.
Type:
Grant
Filed:
April 20, 2010
Date of Patent:
May 29, 2012
Assignee:
Agensys, Inc.
Inventors:
Arthur B. Raitano, Pia M. Challita-Eid, Mary Faris, Rene S. Hubert, Wangmao Ge, Aya Jakobovits
Abstract: A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
Type:
Grant
Filed:
January 23, 2009
Date of Patent:
May 8, 2012
Assignee:
Agensys, Inc.
Inventors:
Arthur B. Raitano, Mary Faris, Rene S. Hubert, Daniel Afar, Wangmao Ge, Pia M. Challita-Eid, Aya Jakobovits
Abstract: A novel gene (designated 213P1F11) and its encoded protein, and variants thereof, are described wherein 213P1F11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 213P1F11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 213P1F11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 213P1F11 can be used in active or passive immunization.
Type:
Grant
Filed:
January 21, 2009
Date of Patent:
May 8, 2012
Assignee:
Agensys, Inc.
Inventors:
Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
Abstract: A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization.
Type:
Grant
Filed:
January 5, 2011
Date of Patent:
May 1, 2012
Assignee:
Agensys, Inc.
Inventors:
Pia M. Challita-Eid, Arthur B. Raitano, Mary Faris, Rene S. Hubert, Karen Jane Meyrick Morrison, Robert Kendall Morrison, Wangmao Ge, Aya Jakobovits
Abstract: A novel gene (designated 121P1F1) and its encoded protein, and variants thereof, are described wherein 121P1F1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P1F1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P1F1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 121P1F1 can be used in active or passive immunization.
Type:
Application
Filed:
September 23, 2011
Publication date:
March 29, 2012
Applicant:
AGENSYS, INC.
Inventors:
Pia M. CHALLITA-EID, Rene S. Hubert, Arthur B. Raitano, Mary Faris, Daniel E. H. Afar, Wangmao Ge, Aya Jakobovits
Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
Type:
Application
Filed:
April 8, 2011
Publication date:
March 15, 2012
Applicants:
Agensys, Inc., The Regents of the University of California
Inventors:
Robert E. Reiter, Owen N. Witte, Douglas C. Saffran, Aya Jakobovitz